Royal London Asset Management Ltd. Has $92.29 Million Position in Halozyme Therapeutics, Inc. $HALO

Royal London Asset Management Ltd. increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 19.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,371,271 shares of the biopharmaceutical company’s stock after purchasing an additional 228,014 shares during the quarter. Royal London Asset Management Ltd.’s holdings in Halozyme Therapeutics were worth $92,287,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the stock. Vontobel Holding Ltd. acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth approximately $255,000. Boston Partners boosted its holdings in shares of Halozyme Therapeutics by 9.5% during the fourth quarter. Boston Partners now owns 487,069 shares of the biopharmaceutical company’s stock worth $33,112,000 after purchasing an additional 42,266 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Halozyme Therapeutics by 124.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 733,562 shares of the biopharmaceutical company’s stock worth $49,369,000 after purchasing an additional 406,595 shares during the period. Federation des caisses Desjardins du Quebec boosted its holdings in shares of Halozyme Therapeutics by 12.3% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 9,278 shares of the biopharmaceutical company’s stock worth $624,000 after purchasing an additional 1,016 shares during the period. Finally, DRW Securities LLC acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth approximately $230,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Down 1.7%

HALO opened at $69.50 on Friday. The firm’s 50-day simple moving average is $67.51 and its 200-day simple moving average is $68.76. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. Halozyme Therapeutics, Inc. has a twelve month low of $51.06 and a twelve month high of $82.22. The firm has a market cap of $8.24 billion, a price-to-earnings ratio of 25.00, a PEG ratio of 0.29 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. During the same quarter in the prior year, the firm earned $1.11 EPS. The firm’s quarterly revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Insider Activity

In related news, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $66.21, for a total transaction of $107,591.25. Following the transaction, the director owned 43,669 shares in the company, valued at $2,891,324.49. This represents a 3.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $51,886,572.40. This trade represents a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 93,250 shares of company stock worth $6,299,746. 2.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Morgan Stanley reduced their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. TD Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. UBS Group reiterated a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Finally, Wells Fargo & Company lifted their target price on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. Eight investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.60.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.